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treatment of inﬂammatory disorders. A series of ﬁfteen pyrazolyl urea derivatives (3a–o) were synthesized
and evaluated for their p38α MAPK inhibition and antioxidant potential. Compounds 3a–e, 3g and 3h
showed low micromolar range potency (IC50 values ranging from 0.0377 1.56 to 0.0697 0.07 mmol/L)
compared to the standard inhibitor SB 203580 (IC50 ¼ 0.043 7 3.62 mmol/L) when evaluated for p38α
MAPK inhibition by an immunosorbent-based assay. Antioxidant activity was measured by a 2,20-
diphenyl-1-picryl hydrazyl radical (DPPH) free radical scavenging method and one of the compounds, 3c,
showed better percentage antioxidant activity (75.06%) compared to butylated hydroxy anisole (71.53%)
at 1 mmol/L concentration. Compounds 3a–e, 3g and 3h showed promising in vivo anti-inﬂammatory
activity (ranging from 62.25% to 80.93%) in comparison to diclofenac sodium (81.62%). The ulcerogenic
liability and lipid peroxidation activity of these compounds were observed to be less in comparison to
diclofenac sodium. These compounds also potently inhibited the lipopolysaccharide (LPS)-induced TNF-
α release in mice (ID50 of 3a–c ¼ 19.98, 11.32 and 9.67 mg/kg, respectively). Among the screened
compounds, derivative 3c was found to be the most potent and its binding mode within the p38αMAPK is
also reported.
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Figure 1 Compound structures of (A) SB 203580 and (B) BIRB 796
(Doramapimod).
Kanagasabai Somakala, Mohammad Amir21. Introduction
Inﬂammation is a multifactorial, protective attempt of the non-speciﬁc
immune system. In response to infection stimulus, monocytes/macro-
phages lineage cells are activated, thereby generating an inﬂammatory
environment by secreting proinﬂammatory cytokines. It is an important
aspect in rheumatoid arthritis, osteoarthritis, Alzheimer's disease and
obesity related diseases1. Non-steroidal anti-inﬂammatory drugs
(NSAIDs) are amongst the most widely prescribed agents for the
management of various inﬂammatory diseases2,3. NSAIDs act by
counteracting the cyclooxygenase (COX) that converts arachidonic
acid into prostaglandins in inﬂammatory processes. Commonly used
NSAIDs, such as aspirin, indomethacin and diclofenac, are non-
selective inhibitors and are responsible for adverse side effects, such as
gastric ulceration, bleeding and renal function suppression4. There are
at least two mammalian COX isoforms5,6. COX-1 is constitutive and
provides cytoprotection in the gastrointestinal (GI) tract, while COX-2
is induced and responsible for pro-inﬂammatory conditions4. Various
selective COX-2 inhibitors, such as celecoxib, rofecoxib and valde-
coxib, showed anti-inﬂammatory activity with minimum gastric side
effects7. Unfortunately, selective COX-2 inhibitors were found to cause
cardiovascular side effects8. Therefore, in view of the GI toxicity of
conventional NSAIDs and the adverse cardiovascular side effects of
selective COX-2 inhibitors, there is a need to develop anti-
inﬂammatory agents with an improved safety proﬁle.
p38α mitogen activated protein kinase (MAPK) has attracted
considerable attention as a major target in developing anti-
inﬂammatory drugs. Activated p38α phosphorylates a range of
intracellular protein substrates that transcriptionally regulate the
biosynthesis of inﬂammatory cytokines like tumor necrosis factor–α
(TNFα) and interleukin-1β (IL-1β)9. The identiﬁcation of p38 MAPK
as the target of some pyridinyl-imidazole compounds, e.g. SB203580
(Fig. 1A), conﬁrmed the role of this intracellular enzyme in the
regulation of many physiological and pathological states and
reinforced the importance of its modulation in the therapy of many
inﬂammatory diseases10. p38αMAPK belongs to the serine/threonine
family of kinases and is a key enzyme of a cascade leading to the
production of pro-inﬂammatory cytokines, such as IL-1β and TNF-
α11. Excessive levels of these cytokines are known to be involved in
the progression of many inﬂammatory disorders, such as rheumatoid
arthritis, inﬂammatory bowel disease, and psoriasis12–14. TNF-α is a
major pleiotropic pro-inﬂammatory cytokine and is known to activate
platelets and also participates in the genesis of fever and anemia15.
Increased production of TNF-α also modulates processes, such as
immune cell activation, proliferation, apoptosis and leukocyte migra-
tion and is thereby associated with many inﬂammatory diseases, like
Crohn's disease, psoriasis, multiple sclerosis and rheumatoid arthri-
tis16. p38α MAPK inhibition is therefore a promising therapeutic
strategy to block the biosynthesis of TNF-α.
Pyrazole derivatives are an important class of heterocycles because
of their diverse pharmacological properties, such as antioxidant, anti-
inﬂammatory, antimicrobial and anti-viral/anti-tumor effects. Rofe-
coxib and celecoxib (selective COX-2 inhibitors) having a pyrazole
moiety have exhibited signiﬁcant anti-inﬂammatory activity with
reduced GI toxicity. Furthermore, pyrazoles17 and pyrazolyl urea
derivatives have also been reported to be potential anti-inﬂammatory
agents18–20. Compound BIRB-79620 (Fig. 1B) having pyrazolyl urea
moiety has shown signiﬁcant anti-inﬂammatory activity through p38α
MAPK and TNF-α inhibition and had advanced into clinical trials.
Encouraged by these observations and in the course of our
research program on the synthesis of ﬁve membered heterocyclic
compounds as anti-inﬂammatory agents10,21-24, we report hereinPlease cite this article as: Somakala Kanagasabai, Amir Mohammad. Synth
derivatives as potential anti-inﬂammatory agents. Acta Pharmaceutica Sinicthe synthesis and evaluation of some new pyrazolyl urea deriva-
tives as potential anti-inﬂammatory agents.2. Results and discussion
2.1. Chemistry
The titled compounds 3a–o were synthesized as illustrated in
Scheme 1. The pyrazoles 1a–o were synthesized as reported earlier25.
Compounds 1a–o were then treated with 4-nitrophenylchloroformate in
acetonitrile in the presence of pyridine to afford phenylcarbamate
derivatives 2a–o. The pyrazolyl urea derivatives 3a–o were synthesized
by treating compounds 2a–o with ammonium acetate in THF in the
presence of triethylamine. Many literature revealed the use of
benzylisocyanate for converting amino groups into ureas. In the present
study, benzylisocyanate was used for the preparation of urea derivatives
but the reaction failed to yield the desired products. Further literature
surveys revealed that amines when treated with 4-nitrophenylchlor-
oformate, followed by the treatment with ammonium acetate, provided
the corresponding ureas in high yield and purity even in aqueous
environment. Following this method the titled compounds were
obtained in good yields and were found to be pure.
The NH2 protons of the pyrazoles 1a–o were observed at
δ 5.17–5.24, which disappeared in the phenyl carbamate derivatives
2a–o. Appearance of a singlet for CONH protons from δ 10.21–10.47
conﬁrmed the formation of phenyl carbamate derivatives. The forma-
tion of 3a–o was conﬁrmed by the appearance of a singlet for NH2
protons from δ 6.12–6.23 showing the presence of a urea group in the
compounds. Compounds 3a–o also showed a singlet for the CONH
protons from δ 10.13 to 10.55. The 13C NMR spectral data of 3a–oesis, characterization and pharmacological evaluation of pyrazolyl urea
a B (2016), http://dx.doi.org/10.1016/j.apsb.2016.08.006
Scheme 1 Reaction protocol for the synthesis of 3a–o. Reagent and conditions: (i) 4-nitrophenylchloroformate, pyridine, CH3CN; (ii) ammonium
acetate, Et3N, THF.
Table 1 IC50 values against p38α MAPK and XP docking
glide score of 3a–o and the standard, SB 203580.
Pyrazolyl urea derivatives as potential anti-inﬂammatory agents 3showed characteristic peaks for C¼O carbons from δ 170.11 to
171.96. The pyrazole carbons were detected at δ 159.21 to 161.48
(pyrazole C3), δ 102.48 to 105.68 (pyrazole C4) and δ 150.97 to 159.66
(pyrazole C5). The OCH2 carbon showed distinct peaks at δ 70.19 to
72.54. Mass spectra of compounds 3a–o showed molecular ion peaks
Mþ at an m/z corresponding to their molecular formula.Compd. R IC50 value (mmol/L)
a Glide scoreb
3a 2-Cl 0.03970.04 8.197
3b 3-Cl 0.03971.50 8.782
3c 4-Cl 0.03771.56 8.872
3d 3,4-diCl 0.07970.65 8.083
3e 4-F 0.04870.01 8.705
3f 4-F-3-Cl 0.11070.17 9.175
3g 4-Br 0.04271.22 8.818
3h 4-NO2 0.06770.95 7.610
3i 2,4-diNO2 0.112 70.04 7.159
3j 2-CH3 0.12371.74 8.227
3k 3-CH3 0.21070.11 8.520
3l 4-CH3 0.16970.07 8.945
3m 2,6-diCH3 0.27074.22 7.567
3n 2-OCH3 0.20670.37 8.012
3o 4-OCH3 0.17070.87 7.753
SB 203580 – 0.04373.62 8.795
aMean 7 SEM of three experiments.
bGlide score denotes g score obtained for docking with p38α
MAPK (PDB ID: 3D83).2.2. p38α MAPK assay
The modulation of p38α MAPK activity by all the synthesized
compounds 3a–o was determined in an enzyme assay measuring the
inhibition of the p38α MAPK mediated ATF-2 phosphorylation.
Compound 3c with a 4-chlorophenyl group at position 1 of the
pyrazole ring exhibited the strongest p38α MAPK inhibition (IC50 ¼
0.037 7 1.56 mmol/L) in comparison to the reference standard, SB
203580 (IC50 ¼ 0.043 7 3.62 mmol/L). Substitution of the 4-
chlorophenyl group by 2-chloro (3a), 3-chloro (3b), 4-ﬂuoro (3e)
and 4-bromo (3g) groups also led to similar p38αMAPK activity (IC50
¼ 0.0397 0.04, 0.0397 1.50, 0.0487 0.01, 0.0427 1.22 mmol/L,
respectively). The IC50 value was decreased slightly for compound 3h
having a 4-nitro group (IC50 ¼ 0.067 7 0.95 mmol/L). Replacement
with a disubstituted electron withdrawing groups, such as 3,4-dichloro
(3d), 2,4-dinitro (3i) and 4-ﬂuoro-3-chloro (3f), resulted in further
decrease of p38α MAPK inhibitory activity (IC50 ¼ 0.079 7 0.65,
0.1127 0.04 and 0.1107 0.17 mmol/L, respectively). When electron
withdrawing groups were replaced with electron donating groups like
2-methyl (3j), 3-methyl (3k), 4-methyl (3l), 2-methoxy (3n) and 4-
methoxy (3o), led to a further decrease of activity (IC50 ranging from
0.123 7 1.74 to 0.210 7 0.11 mmol/L). It was observed that when
these electron donating groups were replaced by disubstituted methyl
group (2,6-dimethyl, 3m), the activity was found to be minimum (IC50
¼ 0.270 7 4.22 mmol/L) (Table 1). Thus the initial activity proﬁle
suggests that electron withdrawing groups attached to the position 1 of
pyrazole ring were more active than electron donating groups.
Furthermore, monosubstituted compounds were found to be more
active than disubstituted compounds. On the basis of these results,
seven compounds (3a–e, 3g and 3h) showing good inhibitory activity
were selected for the in vivo anti-inﬂammatory activity screening.Please cite this article as: Somakala Kanagasabai, Amir Mohammad. Synth
derivatives as potential anti-inﬂammatory agents. Acta Pharmaceutica Sinic2.3. Antioxidant activity
In this study all the synthesized compounds were evaluated for
their free radical scavenging property by measuring the decrease in
the absorption of the stable 2,20-diphenyl-1-picryl hydrazyl radical
(DPPH) at 517 nm. This bleaching occurs when the odd electron
of the radical is paired and is independent of any enzymaticesis, characterization and pharmacological evaluation of pyrazolyl urea
a B (2016), http://dx.doi.org/10.1016/j.apsb.2016.08.006
Figure 2 Antioxidant activity of derivatives 3a–o. Compounds 3j,
3n and 3o did not exhibit signiﬁcant antioxidant activity. Data are
expressed as mean 7 SD, n¼3. *Po0.05 compared to BHA. BHA:
butylated hydroxy anisole.
Kanagasabai Somakala, Mohammad Amir4activity. All the tested compounds showed antioxidant activity
ranging from 75.06% to 31.75% when compared to a standard
butylated hydroxy anisole (BHA) (71.53%). The most active
compound of the series was found to be 3c showing 75.06%
antioxidant activity. Unfortunately compounds 3j, 3n and 3o did
not exhibit any signiﬁcant antioxidant activity (Fig. 2).2.4. Anti-inﬂammatory activity
Compounds 3a–e, 3g and 3h showing good p38α MAPK
inhibitory activity (IC50 ranging from 0.037 7 1.56 to 0.079 7
0.65 mmol/L) were further evaluated for their anti-inﬂammatory
activity (in vivo) by the carrageenan-induced rat paw edema
method. The compounds and standard drug, diclofenac sodium,
were tested at an equimolar oral dose (10 mg/kg body weight). TheTable 2 Anti-inﬂammatory activity of 3a–e, 3g, 3h and
diclofenac sodium.
Compd. Increase in
paw edema
(mL)a
Inhibition (%) Activity
relative to
diclofenac
sodium
3a 0.4070.08 76.19b 93.23
3b 0.3770.20 78.06b 95.52
3c 0.3270.06 80.93b 99.03
3d 0.6470.05 62.25 76.17
3e 0.4770.16 72.33 88.50
3g 0.4470.06 74.01b 90.56
3h 0.5370.12 68.38 83.67
Control 1.6970.04 – –
Diclofenac
sodium
0.3170.13 81.72 100
– not applicable.
aData are expressed as mean7SEM, and analyzed by Student's t-
test for n¼6.
bValues are statistically signiﬁcant compared to control group
(Po0.05).
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62.25% to 80.93%, whereas the standard drug showed 81.72%
inhibition after 4h. It was observed that compound 3c having a 4-
chloro group showing high p38α MAPK activity also showed the
highest anti-inﬂammatory activity (80.93% inhibition). Replace-
ment of 4-chloro group by 2-chloro (3a) and 3-chloro (3b) groups
resulted in a slight decrease of activity (76.19% and 78.06%
inhibition, respectively). Substitution with a 4-ﬂuoro (3e), 4-bromo
(3g) and 4-nitro (3h) groups resulted in further decrease of anti-
inﬂammatory activity (72.33%, 74.01% and 68.38% inhibition,
respectively). Compound 3d having a disubstituted group (3,4-
dichloro) showed minimum anti-inﬂammatory activity (62.25%
inhibition, Table 2). It was observed that monosubstituted electron
withdrawing groups in the phenyl ring attached to the pyrazole
nucleus showed good anti-inﬂammatory activity in both the
in vitro and in vivo models.2.5. Ulcerogenic potential and lipid peroxidation
Compounds 3a–e, 3g and 3h were also tested for their ulcerogenic
activity at an oral dose of 30 mg/kg. Compound 3c showed minimum
ulcerogenicity (severity index 0.58 7 0.37). Compounds 3a, 3b, 3d,
3e, 3g and 3h also showed reduction in severity index (ranging from
0.677 0.25 to 1.087 0.37) superior to the standard drug, diclofenac
(severity index 1.83 7 0.27) (Table 3). Thus it was observed that the
tested compounds have better GI safety proﬁle than the standard drug.
The compounds showing high anti-inﬂammatory activity and
reduced ulcerogenic potential were also tested for their lipid peroxida-
tion, which was measured as nmol of malondialdehyde (MDA) per
100 mg of gastric mucosal tissue. The control group showed
3.26 7 0.12 nmol/100 mg of lipid peroxidation, whereas diclofenac
sodium (standard drug) showed 6.52 7 0.42 nmol/100 mg MDA. It
was found that all the tested compounds showed reduced lipid
peroxidation superior to the standard drug except compounds 3d
and 3h, which showed slightly higher lipid peroxidation (Table 3).Table 3 Ulcerogenic, lipid peroxidation and TNF-α inhibi-
tion activities of 3a–e, 3g, 3h and the standards.
Compd. Severity
indexa
Lipid
peroxidation
(nmol MDA/
100 mg
tissue)a
TNF-α
inhibition
(%)a
ID50
(mg/
kg)
Control 0.0070.00 3.2670.12 - -
3a 0.6770.25b 5.4770.44b 60.8772.65b 19.98
3b 0.6770.40b 5.1970.48b 62.4570.07b 11.32b
3c 0.5870.37b 5.1270.55b 62.5670.24 9.67b
3d 1.0870.37b 6.8370.48b 52.6072.16 -
3e 0.8370.22 6.0870.15 57.3473.05 -
3g 0.7570.27 6.0270.17a 58.1370.28 -
3h 0.9170.20 6.8470.18 52.7672.08 -
Diclofenac
sodium
1.8370.27 6.5270.42 - -
SB 203580 – – 52.1171.08b 28.40b
– not applicable.
aData were expressed as mean7SEM and analyzed by Student's
t-test for n¼6.
bValues are statistically signiﬁcant compared to respective
standard (Po0.05).
esis, characterization and pharmacological evaluation of pyrazolyl urea
a B (2016), http://dx.doi.org/10.1016/j.apsb.2016.08.006
Pyrazolyl urea derivatives as potential anti-inﬂammatory agents 5Thus it may be concluded that the protection of gastric mucosa might
be related to the inhibition of lipid peroxidation.
2.6. TNF-α production inhibition evaluation
Compounds 3a–e, 3g and 3h were also evaluated for their
inhibitory activity against lipopolysaccharide (LPS)-induced
TNF-α production in mice. Compound 3c was found to be most
effective with an ID50 value of 9.67 mg/kg, which was more active
than that of SB 203580 (ID50 ¼ 28.40 mg/kg). Analogs 3a and 3b
also demonstrated good TNF-α inhibitory efﬁcacy with ID50
values of 19.98 and 11.32 mg/kg, respectively (Table 3).
2.7. Docking study
The crystal structures of p38α MAPK complexed with inhibitors were
selected as the protein target used for the docking study. Among the
compounds studied for p38αMAPK inhibition, compound 3c showing
high p38α MAPK activity (IC50¼ 0.0377 1.56 mmol/L) and in vivo
anti-inﬂammatory activity (80.93% inhibition) was found to be potent.
The most stable docking pose was selected according to the best
docking scored conformation predicted by the Glide scoring function.
The orientation and conformation of the docked compound are similar
to those of SB 203580 (p38α prototype inhibitor). The binding modes
of 3c and the prototype inhibitor (SB 203580) to a rearranged (DFG-
out) form of p38α are presented in Fig. 3. Compound 3c and SB
203580 showed a common interaction with amino acid residue ASP
168 and LYS 53. The nitrogen atom of pyrazole scaffold of 3c formed
hydrogen bond with the backbone of ASP 168 (N….HN, 2.65 Å). The
oxygen atom in the carbonyl functionality in 3c forms a hydrogen bond
with the side chain of LYS 53 (C¼O….HN, 3.84 Å) residue in theFigure 3 (A) Docked pose of compound 3c (green color) represented
interaction (yellow dashed lines) with ASP 168, LYS 53, ALA 51 and
(C) Docked pose of SB 203580 (pink color) represented as tube in the bin
dashed lines) with ASP 168, GLU 71 and π-cation interaction with LYS 53;
203580 (pink color) in the binding site.binding pocket, shown in Fig. 3A. Moreover the urea moiety forms
additional hydrogen bonds with THR 106 (H….OH, 2.14 Å) and Ala
51 (O….HN, 2.25 Å; O….HN, 3.73 Å). The receptor surface view of
compound 3c in the protein is shown in Fig. 3B and superimposed
docked pose of compound 3c with SB 203580 is also represented in
Fig. 3D, which conﬁrms their identical orientation and alignment.
Furthermore, the docked pose of SB 203580 revealed that the pyrazole
NH and N atoms formed two hydrogen bonds with the side chain of
GLU 71 (1.89 Å, H…O) and backbone of ASP 168 (2.70 Å, N…H) in
the binding pocket. Finally, SB 203580 adopts a favorable conforma-
tion in which one of the phenyl ring formed a π-cation interaction with
LYS 53 (4.21 Å, Phenyl…þHN). The glide scores of 3a–o were in the
range of 9.175 to 7.159. Compound 3c showed a glide score of
8.872 and SB 203580 had a glide score of 8.795 (Table 1).3. Conclusions
Fifteen new pyrazolyl urea derivatives have been synthesized and
subjected to in vitro screening for p38α MAPK inhibition and
antioxidant activities. Moreover, the in vivo anti-inﬂammatory,
ulcerogenic, lipid peroxidation and TNF-α inhibition activities of
the compounds have also been tested. The results of the in vitro
activities revealed that compounds 3a–e, 3g and 3h bearing
2-chloro, 3-chloro, 4-chloro, 3,4-dichloro, 4-ﬂuoro, 4-bromo and
4-nitro phenyl groups, respectively, at the position 1 of pyrazole
ring showed better p38α MAPK inhibition as compared to the
standard inhibitor (SB 203580). Compound 3c was found to have
superior antioxidant activity in comparison to the reference
compound, BHA. It was noted that compound 3c was a potent
anti-inﬂammatory agent comparable to the standard reference drug
diclofenac sodium. This compound also showed reducedas tube in the binding site of p38α MAPK showing hydrogen bond
THR 106; (B) Receptor surface view of compound 3c (green color)
ding site of p38α MAPK showing hydrogen bond interaction (yellow
(D) Superimposed docked pose of compound 3c (green color) with SB
Figure 4 Structure of compound 4a
Kanagasabai Somakala, Mohammad Amir6ulcerogenic potential and the weakest activity in inducing oxida-
tive stress in tissues compared to the standard drug. Compound 3c
also demonstrated good inhibition of LPS-induced TNF-α produc-
tion in mice. It was observed that compounds showing signiﬁcant
in vitro p38α MAPK activity also showed good in vivo anti-
inﬂammatory and TNF-α inhibitory activities. In summary, among
all the tested compounds, 1-[4-[5-(4-(benzyloxy)phenyl)-1-(4-
chlorophenyl)-1H-pyrazol-3-yl]phenyl]urea (3c) was the most
potent anti-inﬂammatory agent having reduced ulcerogenic liabi-
lity and lipid peroxidation.
Our earlier studies on pyrazole derivatives having a sulfona-
mide moiety24 also showed good anti-inﬂammatory and TNF-α
inhibitory activities. Compound 4a (Fig. 4) having 2-chloro group
at the position 1 of pyrazole ring has shown high anti-
inﬂammatory and TNF-α inhibitory activities. Whereas in the
present studies, pyrazole derivatives having a urea pharmacophore
also showed comparable anti-inﬂammatory activity along with
improved TNF-α inhibitory properties. Furthermore, pyrazolyl
urea derivatives were also studied for their p38α MAPK inhibition
and showed signiﬁcant activity.4. Experimental
4.1. Chemistry
Melting points (mp, 1C) were recorded using a Labtronics digital
melting point apparatus (Haryana, India) and were uncorrected. IR
spectra were recorded on a Perkin-Elmer 1720 FTIR spectrometer
(New York, USA). 1H NMR spectra (400 MHz) and 13C NMR
spectra (100 MHz) were obtained on a Bruker Avance NMR
spectrometer (Zurich, Switzerland) using tetramethysilane (TMS)
as the internal reference with complete proton decoupling. MS
analyses were performed on a Jeol SX-102 spectrometer (Tokyo,
Japan). Thin layer chromatography (TLC) was performed on silica
gel G (Merck) and spots were visualized under the ultraviolet light
(UV 254 nm). Elemental analyses (C, H and N) were conducted
using a CHNS Vario EL III machine (Elementar Analysen systeme
GmbH, Germany).
4.1.1. 4-[5-[4-(Benzyloxy)phenyl]-1-substituted phenyl-1H-
pyrazol-3-yl]anilines (1a–o)
The compounds were synthesized using our earlier reported
method24.
4.1.2. General method for the synthesis of 4-nitrophenyl 4-[5-(4-
(benzyloxy)phenyl)-1-substituted-1H-pyrazol-3-yl]
phenylcarbamates (2a–o)
A mixture of one equivalent of the 4-[5-(4-(benzyloxy)phenyl)-1-
substituted phenyl-1H-pyrazol-3-yl]anilines 1a–o (5 mmol), ﬁvePlease cite this article as: Somakala Kanagasabai, Amir Mohammad. Synth
derivatives as potential anti-inﬂammatory agents. Acta Pharmaceutica Sinicequivalents of 4-nitrophenylchloroformate (25 mmol) and
5 equivalents of pyridine (5 mL) in the presence of acetonitrile
(20 mL) was stirred at room temperature for 3–5 h. The reaction
mixture was quenched with water (100 mL). An oily material thus
obtained was kept aside overnight at room temperature. Solid thus
obtained was ﬁltered, washed with water, dried and recrystallized
from ethanol.
4.1.2.1. 4-Nitrophenyl-4-[5-(4-(benzyloxy)phenyl)-1-(2-chloro-
phenyl)-1H-pyrazol-3-yl]phenyl carbamate (2a). Yield 82%; mp
157–158 1C; IR (cm1, KBr): 3031 (C-H), 1670 (CONH), 1598
(C¼N); 1H NMR (DMSO-d6): δ 10.27 (s, 1H, CONH, D2O
exchangeable), 7.42–7.89 (m, 21H, Ar-H), 7.05 (s, 1H, pyrazole-
H-4), 5.12 (s, 2H, OCH2); Anal. Calcd. for C35H25ClN4O5: C,
68.13; H, 4.08; N, 9.08; Found: C, 68.20; H, 4.02; N, 9.11.
4.1.2.2. 4-Nitrophenyl-4-[5-(4-(benzyloxy)phenyl)-1-(3-chloro-
phenyl)-1H-pyrazol-3-yl]phenyl carbamate (2b). Yield 84%; mp
154–156 1C; IR (cm1, KBr): 3031 (C–H), 1666 (C¼O), 1592
(C¼N); 1H NMR (DMSO-d6): δ 10.25 (s, 1H, CONH, D2O
exchangeable), 7.47–7.88 (m, 21H, Ar–H), 7.02 (s, 1H, pyrazole-
H-4), 5.16 (s, 2H, OCH2); Anal. Calcd. for C35H25ClN4O5: C,
68.13; H, 4.08; N, 9.08; Found: C, 68.23; H, 4.14; N, 9.07.
4.1.2.3. 4-Nitrophenyl-4-[5-(4-(benzyloxy)phenyl)-1-(4-chloro-
phenyl)-1H-pyrazol-3-yl]phenyl carbamate (2c). Yield 79%; mp
163–164 1C; IR (cm1, KBr): 3035 (C-H), 1668 (CONH), 1595
(C¼N); 1H NMR (DMSO-d6): δ 10.36 (s, 1H, CONH, D2O
exchangeable), 7.43–7.89 (m, 21H, Ar-H), 7.09 (s, 1H, pyrazole-
H-4), 5.21 (s, 2H, OCH2); Anal. Calcd. for C35H25ClN4O5: C,
68.13; H, 4.08; N, 9.08; Found: C, 68.06; H, 4.03; N, 9.05.
4.1.2.4. 4-Nitrophenyl-4-[5-(4-(benzyloxy)phenyl)-1-(3,4-dichlor-
ophenyl)-1H-pyrazol-3-yl]phenyl carbamate (2d). Yield 77%; mp
158–159 1C; IR (cm1, KBr): 3031 (C-H), 1672 (CONH), 1596
(C¼N); 1H NMR (DMSO-d6): δ 10.47 (s, 1H, CONH, D2O
exchangeable), 7.42–7.91 (m, 20H, Ar-H), 7.11 (s, 1H, pyrazole-
H-4), 5.13 (s, 2H, OCH2); Anal. Calcd. for C35H24Cl2N4O5: C,
64.52; H, 3.71; N, 8.60; Found: C, 64.56; H, 3.64; N, 8.65.
4.1.2.5. 4-Nitrophenyl-4-[5-(4-(benzyloxy)phenyl)-1-(4-ﬂuoro-
phenyl)-1H-pyrazol-3-yl]phenyl carbamate (2e). Yield 82%; mp
186–187 1C; IR (cm1, KBr): 3032 (C-H), 1663 (CONH), 1585
(C¼N); 1H NMR (DMSO-d6): δ 10.44 (s, 1H, CONH, D2O
exchangeable), 7.39–7.88 (m, 21H, Ar-H), 7.05 (s, 1H, pyrazole-
H-4), 5.18 (s, 2H, OCH2); Anal. Calcd. for C35H25FN4O5: C,
69.99; H, 4.20; N, 9.33; Found: C, 69.96; H, 4.13; N, 9.27.
4.1.2.6. 4-Nitrophenyl-4-[5-(4-(benzyloxy)phenyl)-1-(4-ﬂuoro-
3-chlorophenyl)-1H-pyrazol-3-yl]phenyl carbamate (2f). Yield
75%; mp 202–203 1C; IR (cm1, KBr): 3033 (C-H), 1672
(CONH), 1590 (C¼N); 1H NMR (DMSO-d6): δ 10.21 (s, 1H,
CONH, D2O exchangeable), 7.42–7.85 (m, 20H, Ar-H), 7.08 (s,
1H, pyrazole-H-4), 5.16 (s, 2H, OCH2); Anal. Calcd. for
C35H24ClFN4O5: C, 66.20; H, 3.81; N, 8.82; Found: C, 66.16;
H, 3.83; N, 8.75.
4.1.2.7. 4-Nitrophenyl-4-[5-(4-(benzyloxy)phenyl)-1-(4-bromo-
phenyl)-1H-pyrazol-3-yl]phenyl carbamate (2g). Yield 77%; mp
171–172 1C; IR (cm1, KBr): 3031 (C-H), 1658 (CONH), 1590
(C¼N); 1H NMR (DMSO-d6): δ 10.26 (s, 1H, CONH, D2O
exchangeable), 7.40–7.84 (m, 21H, Ar-H), 7.05 (s, 1H, pyrazole-
H-4), 5.16 (s, 2H, OCH2); Anal. Calcd. for C35H25BrN4O5: C,
63.55; H, 3.81; N, 8.47; Found: C, 63.61; H, 3.89; N, 8.45.esis, characterization and pharmacological evaluation of pyrazolyl urea
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Pyrazolyl urea derivatives as potential anti-inﬂammatory agents 74.1.2.8. 4-Nitrophenyl-4-[5-(4-(benzyloxy)phenyl)-1-(4-nitrophe-
nyl)-1H-pyrazol-3-yl]phenyl carbamate (2h). Yield 81%; mp
188–189 1C; IR (cm1, KBr): 3030 (C-H), 1671 (CONH), 1594
(C¼N); 1H NMR (DMSO-d6): δ 10.33 (s, 1H, CONH, D2O
exchangeable), 7.36–7.82 (m, 21H, Ar-H), 7.07 (s, 1H, pyrazole-
H-4), 5.09 (s, 2H, OCH2); Anal. Calcd. for C35H25N5O7: C, 66.98;
H, 4.02; N, 11.16; Found: C, 66.96; H, 4.09; N, 11.09.
4.1.2.9. 4-Nitrophenyl-4-[5-(4-(benzyloxy)phenyl)-1-(2,4-dinitro-
phenyl)-1H-pyrazol-3-yl]phenyl carbamate (2i). Yield 89%; mp
178–179 1C; IR (cm1, KBr): 3031 (C-H), 1673 (C¼O), 1597
(C¼N); 1H NMR (DMSO-d6): δ 10.39 (s, 1H, CONH, D2O
exchangeable), 7.42–7.86 (m, 20H, Ar-H), 7.05 (s, 1H, pyrazole-
H-4), 5.16 (s, 2H, OCH2); Anal. Calcd. for C35H24N6O9: C, 62.50;
H, 3.60; N, 12.49; Found: C, 62.56; H, 3.68; N, 12.54.
4.1.2.10. 4-Nitrophenyl 4-[5-(4-(benzyloxy)phenyl)-1-(2-methyl-
phenyl)-1H-pyrazol-3-yl]phenyl carbamate (2j). Yield 81%; mp
181–183 1C; IR (cm1, KBr): 3029 (C-H), 1656 (CONH), 1588
(C¼N); 1H NMR (DMSO-d6): δ 10.29 (s, 1H, CONH, D2O
exchangeable), 7.42–7.84 (m, 21H, Ar-H), 7.05 (s, 1H, pyrazole-
H-4), 5.10 (s, 2H, OCH2), 2.27 (s, 3H, CH3); Anal. Calcd. for
C36H28N4O5: C, 72.47; H, 4.73; N, 9.39; Found: C, 72.52; H,
4.79; N, 9.31.
4.1.2.11. 4-Nitrophenyl 4-[5-(4-(benzyloxy)phenyl)-1-(3-methyl-
phenyl)-1H-pyrazol-3-yl]phenyl carbamate (2k). Yield 84%; mp
184–185 1C; IR (cm1, KBr): 3037 (C-H), 1674 (CONH), 1592
(C¼N); 1H NMR (DMSO-d6): δ 10.34 (s, 1H, CONH, D2O
exchangeable), 7.41–7.87 (m, 21H, Ar-H), 7.05 (s, 1H, pyrazole-
H-4), 5.11 (s, 2H, OCH2), 2.29 (s, 3H, CH3); Anal. Calcd. for
C36H28N4O5: C, 72.47; H, 4.73; N, 9.39; Found: C, 72.48; H,
4.76; N, 9.35.
4.1.2.12. 4-Nitrophenyl 4-[5-(4-(benzyloxy)phenyl)-1-(4-methyl-
phenyl)-1H-pyrazol-3-yl]phenyl carbamate (2l). Yield 81%; mp
185–186 1C; IR (cm1, KBr): 3031 (C-H), 1663 (CONH), 1585
(C¼N); 1H NMR (DMSO-d6): δ 10.38 (s, 1H, CONH, D2O
exchangeable), 7.36–7.93 (m, 21H, Ar-H), 7.05 (s, 1H, pyrazole-
H-4), 5.22 (s, 2H, OCH2), 2.30 (s, 3H, CH3); Anal. Calcd. for
C36H28N4O5: C, 72.47; H, 4.73; N, 9.39; Found: C, 72.53; H,
4.68; N, 9.34.
4.1.2.13. 4-Nitrophenyl-4-[5-(4-(benzyloxy)phenyl)-1-(2,6-
dimethylphenyl)-1H-pyrazol-3-yl]phenyl carbamate (2m). Yield
74%; mp 193–195 1C; IR (cm1, KBr): 3037 (C-H), 1668
(CONH), 1592 (C¼N); 1H NMR (DMSO-d6): δ 10.23 (s, 1H,
CONH, D2O exchangeable), 7.42–7.82 (m, 20H, Ar-H), 7.05 (s,
1H, pyrazole-H-4), 5.12 (s, 2H, OCH2), 2.17 (s, 6H, CH3); Anal.
Calcd. for C37H30N4O5: C, 72.77; H, 4.95; N, 9.17; Found: C,
72.73; H, 4.98; N, 9.24.
4.1.2.14. 4-Nitrophenyl-4-[5-(4-(benzyloxy)phenyl)-1-(2-methox-
yphenyl)-1H-pyrazol-3-yl]phenyl carbamate (2n). Yield 72%; mp
165–166 1C; IR (cm1, KBr): 3029 (C–H), 1661 (CONH), 1595
(C¼N); 1H NMR (DMSO-d6): δ 10.35 (s, 1H, CONH, D2O
exchangeable), 7.42–7.88 (m, 21H, Ar-H), 7.05 (s, 1H, pyrazole-
H-4), 5.18 (s, 2H, OCH2), 3.69 (s, 3H, OCH3); Anal. Calcd. for
C36H28N4O6: C, 70.58; H, 4.61; N, 9.15; Found: C, 70.53; H,
4.68; N, 9.09.
4.1.2.15. 4-Nitrophenyl-4-[5-(4-(benzyloxy)phenyl)-1-(4-methox-
yphenyl)-1H-pyrazol-3-yl]phenyl carbamate (2o). Yield 77%; mp
169–170 1C; IR (cm1, KBr): 3032 (C-H), 1674 (CONH), 1590Please cite this article as: Somakala Kanagasabai, Amir Mohammad. Synth
derivatives as potential anti-inﬂammatory agents. Acta Pharmaceutica Sinic(C¼N); 1H NMR (DMSO-d6): δ 10.41 (s, 1H, CONH, D2O
exchangeable), 7.38–7.92 (m, 21H, Ar-H), 7.03 (s, 1H, pyrazole-
H-4), 5.21 (s, 2H, OCH2), 3.72 (s, 3H, OCH3); Anal. Calcd. for
C36H28N4O6: C, 70.58; H, 4.61; N, 9.15; Found: C, 70.51; H,
4.57; N, 9.11.
4.1.3. General method for the synthesis of 1-[4-[5-(4-
(benzyloxy)phenyl)-1-(substituted phenyl)-1H-pyrazol-3-yl]phenyl]
ureas (3a–o)
A mixture of 4-nitrophenyl-4-[5-(4-(benzyloxy)phenyl)-1-substi-
tuted-1H-pyrazol-3-yl]phenyl carbamates 2a–o (5 mmol) and ammo-
nium acetate (20 mmol) in the presence of triethylamine (20 mmol)
and tetrahydrofuran (20 mL) was stirred at room temperature for
4–6 h. The reaction mixture was then poured into ice water (30 mL)
while stirring. The compound obtained was ﬁltered, washed with
water and dried. The residue thus obtained was triturated in hot
DCM, ﬁltered and recrystallized from ethanol.
4.1.3.1. 1-[4-[5-(4-(Benzyloxy)phenyl)-1-(2-chlorophenyl)-1H-
pyrazol-3-yl]phenyl]urea (3a). Yield 64%; mp 210–211 1C; IR
(cm1, KBr): 3352 (N-H), 3031 (C-H), 1652 (CONH), 1598
(C¼N); 1H NMR (DMSO-d6): δ 10.32 (s, 1H, CONH, D2O
exchangeable), 7.49–8.16 (m, 17H, Ar-H), 7.12 (s, 1H, pyrazole-
H-4), 6.18 (s, 2H, NH2, D2O exchangeable), 5.23 (s, 2H, OCH2);
13C NMR (DMSO-d6): δ 170.17 (C¼O), 161.25 (pyrazole C3),
150.97 (pyrazole C5), 144.74, 138.25, 135.11, 135.07, 134.18,
133.82, 129.78, 129.15, 128.43, 128.38, 128.05, 127.83, 125.62,
122.09, 121.84, 121.09, 117.98, 112.99, 103.97 (pyrazole C4),
72.09 (OCH2); ESI-MS (m/z): 510 [MþH]þ, 511 [Mþ2]þ; Anal.
Calcd. for C29H23ClN4O2: C, 70.37; H, 4.68; N, 11.32; Found: C,
70.41; H, 4.61; N, 11.28.
4.1.3.2. 1-[4-[5-(4-(Benzyloxy)phenyl)-1-(3-chlorophenyl)-1H-
pyrazol-3-yl]phenyl]urea (3b). Yield 58%; mp 192–193 1C; IR
(cm1, KBr): 3344 (N-H), 3038 (C-H), 1656 (CONH), 1592
(C¼N); 1H NMR (DMSO-d6): δ 10.13 (s, 1H, CONH, D2O
exchangeable), 7.38–8.07 (m, 17H, Ar-H), 7.05 (s, 1H, pyrazole-
H-4), 6.16 (s, 2H, NH2, D2O exchangeable), 5.15 (s, 2H, OCH2);
13C NMR (DMSO-d6): δ 171.83 (C¼O), 160.83 (pyrazole C3),
159.07 (pyrazole C5), 151.52, 144.65, 138.27, 136.93, 136.48,
134.72, 130.45, 130.18, 128.90, 128.73, 128.67, 128.42, 125.13,
123.58, 122.38, 121.27, 119.83, 113.79, 105.38 (pyrazole C4),
71.49 (OCH2); ESI-MS (m/z): 510 [MþH]þ, 511 [Mþ2]þ; Anal.
Calcd. for C29H23ClN4O2: C, 70.37; H, 4.68; N, 11.32; Found: C,
70.32; H, 4.63; N, 11.36.
4.1.3.3. 1-[4-[5-(4-(Benzyloxy)phenyl)-1-(4-chlorophenyl)-1H-
pyrazol-3-yl]phenyl]urea (3c). Yield 62%; mp 210–211 1C; IR
(cm1, KBr): 3345 (N-H), 3035 (C-H), 1631 (CONH), 1595
(C¼N); 1H NMR (DMSO-d6): δ 10.25 (s, 1H, CONH, D2O
exchangeable), 7.42–8.09 (m, 17H, Ar-H), 7.07 (s, 1H, pyrazole-
H-4), 6.19 (s, 2H, NH2, D2O exchangeable), 5.16 (s, 2H, OCH2);
13C NMR (DMSO-d6): δ 170.21 (C¼O), 159.67 (pyrazole C3),
158.12 (pyrazole C5), 151.36, 143.25, 138.31, 136.72, 136.16,
135.94, 130.19, 129.87, 128.97, 128.83, 128.58, 128.14, 125.66,
122.93, 122.62, 120.93, 117.61, 113.18, 104.75 (pyrazole C4),
70.56 (OCH2); ESI-MS (m/z): 510 [MþH]þ, 511 [Mþ2]þ; Anal.
Calcd. for C29H23ClN4O2: C, 70.37; H, 4.68; N, 11.32; Found: C,
70.39; H, 4.72; N, 11.39.
4.1.3.4. 1-[4-[5-(4-(Benzyloxy)phenyl)-1-(3,4-dichlorophenyl)-
1H-pyrazol-3-yl]phenyl]urea (3d). Yield 62%; mp 253–254 1C;
IR (cm1, KBr): 3348 (N-H), 3031 (C-H), 1629 (C¼O), 1596esis, characterization and pharmacological evaluation of pyrazolyl urea
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exchangeable), 7.42–8.09 (m, 16H, Ar-H), 7.07 (s, 1H, pyrazole-
H-4), 6.15 (s, 2H, NH2, D2O exchangeable), 5.16 (s, 2H, OCH2);
13C NMR (DMSO-d6): δ 171.65 (C¼O), 160.29 (pyrazole C3),
159.05 (pyrazole C5), 152.07, 144.37, 138.16, 136.54, 136.37,
135.12, 130.86, 130.65, 128.34, 128.14, 128.11, 128.06, 124.95,
123.61, 122.98, 122.65, 119.57, 114.06, 104.32 (pyrazole C4),
71.32 (OCH2); ESI-MS (m/z): 544 [MþH]þ, 545 [Mþ2]þ; Anal.
Calcd. for C29H22Cl2N4O2: C, 65.79; H, 4.19; N, 10.58; Found: C,
65.84; H, 4.22; N, 10.64.
4.1.3.5. 1-[4-[5-(4-(benzyloxy)phenyl)-1-(4-ﬂuorophenyl)-1H-
pyrazol-3-yl]phenyl]urea (3e). Yield 66%; mp 261–262 1C; IR
(cm1, KBr): 3356 (N-H), 3032 (C-H), 1631 (C¼O), 1585
(C¼N); 1H NMR (DMSO-d6): δ 10.44 (s, 1H, CONH, D2O
exchangeable), 7.49–8.16 (m, 17H, Ar-H), 7.14 (s, 1H, pyrazole-
H-4), 6.19 (s, 2H, NH2, D2O exchangeable), 5.23 (s, 2H, OCH2);
13C NMR (DMSO-d6): δ 170.34 (C¼O), 159.21 (pyrazole C3),
158.36 (pyrazole C5), 152.65, 144.16, 138.51, 135.43, 135.23,
134.86, 129.65, 129.12, 128.95, 128.63, 128.44, 127.09, 124.07,
123.54, 121.58, 120.87, 118.43, 114.17, 104.69 (pyrazole C4),
71.62 (OCH2); ESI-MS (m/z): 494 [MþH]þ; Anal. Calcd. for
C29H23FN4O2: C, 72.79; H, 4.84; N, 11.71; Found: C, 72.76; H,
4.90; N, 11.77.
4.1.3.6. 1-[4-[5-(4-(Benzyloxy)phenyl)-1-(3-chloro-4-ﬂuorophe-
nyl)-1H-pyrazol-3-yl]phenyl] urea (3f). Yield 63%; mp 220–
221 1C; IR (cm1, KBr): 3351 (N-H), 3033 (C-H), 1632
(C¼O), 1590 (C¼N); 1H NMR (DMSO-d6): δ 10.21 (s, 1H,
CONH, D2O exchangeable), 7.42–7.82 (m, 16H, Ar-H), 7.10 (s,
1H, pyrazole-H-4), 6.13 (s, 2H, NH2, D2O exchangeable), 5.16 (s,
2H, OCH2);
13C NMR (DMSO-d6): δ 170.69 (C¼O), 159.54
(pyrazole C3), 158.79 (pyrazole C5), 151.94, 144.72, 138.09,
135.17, 135.10, 134.94, 129.89, 129.13, 128.82, 128.78, 128.52,
128.17, 124.37, 123.16, 122.43, 120.96, 117.65, 112.65, 105.66
(pyrazole C4), 72.11 (OCH2); ESI-MS (m/z): 528 [MþH]þ, 529
[Mþ2]þ; Anal. Calcd. for C29H22ClFN4O2: C, 67.90; H, 4.32; N,
10.92; Found: C, 67.84; H, 4.39; N, 10.95.
4.1.3.7. 1-[4-[5-(4-(Benzyloxy)phenyl)-1-(4-bromophenyl)-1H-
pyrazol-3-yl]phenyl]urea (3g). Yield 68%; mp 230–231 1C; IR
(cm1, KBr): 3357 (N-H), 3031 (C-H), 1626 (C¼O), 1590
(C¼N); 1H NMR (DMSO-d6): δ 10.15 (s, 1H, CONH, D2O
exchangeable), 7.42–7.87 (m, 17H, Ar-H), 7.05 (s, 1H, pyrazole-
H-4), 6.23 (s, 2H, NH2, D2O exchangeable), 5.16 (s, 2H, OCH2);
13C NMR (DMSO-d6): δ 171.17 (C¼O), 160.62 (pyrazole C3),
158.12 (pyrazole C5), 151.39, 144.51, 137.62, 136.15, 135.82,
134.15, 130.65, 130.09, 128.73, 128.65, 128.32, 127.85, 125.62,
123.65, 121.54, 120.32, 118.58, 112.29, 103.81 (pyrazole C4),
72.18 (OCH2); ESI-MS (m/z): 554 [MþH]þ, 555 [Mþ2]þ; Anal.
Calcd. for C29H23BrN4O2: C, 64.57; H, 4.30; N, 10.39; Found: C,
64.53; H, 4.37; N, 10.44.
4.1.3.8. 1-[4-[5-(4-(Benzyloxy)phenyl)-1-(4-nitrophenyl)-1H-pyr-
azol-3-yl]phenyl]urea (3H). Yield 61%; mp 215–216 1C; IR
(cm1, KBr): 3341 (N-H), 3030 (C-H), 1631 (C¼O), 1590
(C¼N); 1H NMR (DMSO-d6): δ 10.25 (s, 1H, CONH, D2O
exchangeable), 7.42–8.09 (m, 17H, Ar-H), 7.05 (s, 1H, pyrazole-
H-4), 6.12 (s, 2H, NH2, D2O exchangeable), 5.16 (s, 2H, OCH2);
13C NMR (DMSO-d6): δ 171.39 (C¼O), 161.15 (pyrazole C3),
157.37 (pyrazole C5), 150.62, 143.09, 137.37, 136.12, 136.09,
135.26, 130.73, 129.08, 128.57, 128.42, 128.13, 128.08, 125.37,
123.19, 122.64, 120.43, 118.43, 112.89, 103.07 (pyrazole C4),Please cite this article as: Somakala Kanagasabai, Amir Mohammad. Synth
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C29H23N5O4: C, 68.90; H, 4.59; N, 13.85; Found: C, 68.98; H,
4.62; N, 13.91.
4.1.3.9. 1-[4-[5-(4-(Benzyloxy)phenyl)-1-(2,4-dinitrophenyl)-1H-
pyrazol-3-yl]phenyl]urea (3i). Yield 64%; mp 222–223 1C; IR
(cm1, KBr): 3624, 3346 (N-H), 3031 (C-H), 1626 (C¼O), 1585
(C¼N); 1H NMR (DMSO-d6): δ 10.39 (s, 1H, CONH, D2O
exchangeable), 7.42–7.88 (m, 16H, Ar-H), 7.05 (s, 1H, pyrazole-
H-4), 6.20 (s, 2H, NH2, D2O exchangeable), 5.16 (s, 2H, OCH2);
13C NMR (DMSO-d6): δ 170.74 (C¼O), 160.37 (pyrazole C3),
157.95 (pyrazole C5), 150.38, 142.96, 138.65, 136.09, 135.26,
134.09, 130.56, 129.13, 128.97, 128.32, 128.05, 127.57, 124.92,
123.42, 121.90, 120.56, 119.37, 112.48, 102.48 (pyrazole C4),
70.19 (OCH2); ESI-MS (m/z): 566 [MþH]þ; Anal. Calcd. for
C29H22N6O6: C, 63.27; H, 4.03; N, 15.27; Found: C, 63.33; H,
4.09; N, 15.20.
4.1.3.10. 1-[4-[5-(4-(Benzyloxy)phenyl)-1-(2-methylphenyl)-1H-
pyrazol-3-yl]phenyl]urea (3j). Yield 57%; mp 200–201 1C; IR
(cm1, KBr): 3632, 3347 (N-H), 3029 (C-H), 1639 (C¼O), 1588
(C¼N); 1H NMR (DMSO-d6): δ 10.25 (s, 1H, CONH, D2O
exchangeable), 7.42–7.83 (m, 17H, Ar-H), 7.05 (s, 1H, pyrazole-
H-4), 6.22 (s, 2H, NH2, D2O exchangeable), 5.10 (s, 2H, OCH2),
2.06 (s, 3H, CH3);
13C NMR (DMSO-d6): δ 170.11 (C¼O),
160.96 (pyrazole C3), 158.07 (pyrazole C5), 152.77, 142.08,
138.14, 136.02, 135.87, 135.13, 130.75, 129.62, 128.59, 128.32,
128.17, 127.27, 124.85, 122.96, 121.87, 120.61, 119.01, 114.83,
103.67 (pyrazole C4), 72.54 (OCH2), 17.83 (CH3); ESI-MS (m/z):
490 [MþH]þ; Anal. Calcd. for C30H26N4O2: C, 75.93; H, 5.52; N,
11.81; Found: C, 75.85; H, 5.59; N, 11.76.
4.1.3.11. 1-[4-[5-(4-(Benzyloxy)phenyl)-1-(3-methylphenyl)-1H-
pyrazol-3-yl]phenyl]urea (3k). Yield 55%; mp 202–203 1C; IR
(cm1, KBr): 3635, 3350 (N-H), 3037 (C-H), 1635 (C¼O), 1592
(C¼N); 1H NMR (DMSO-d6): δ 10.25 (s, 1H, CONH, D2O
exchangeable), 7.42–7.81 (m, 17H, Ar-H), 7.05 (s, 1H, pyrazole-
H-4), 6.14 (s, 2H, NH2, D2O exchangeable), 5.11 (s, 2H, OCH2),
2.06 (s, 3H, CH3);
13C NMR (DMSO-d6): δ 170.35 (C¼O),
161.48 (pyrazole C3), 159.53 (pyrazole C5), 152.09, 143.73,
138.95, 135.47, 135.05, 134.85, 129.86, 129.15, 128.83, 128.48,
128.39, 128.11, 125.16, 122.58, 121.74, 120.13, 117.46, 114.61,
104.17 (pyrazole C4), 71.56 (OCH2), 17.18 (CH3); ESI-MS (m/z):
490 [MþH]þ; Anal. Calcd. for C30H26N4O2: C, 75.93; H, 5.52; N,
11.81; Found: C, 75.96; H, 5.55; N, 11.87.
4.1.3.12. 1-[4-[5-(4-(Benzyloxy)phenyl)-1-(4-methylphenyl)-1H-
pyrazol-3-yl]phenyl]urea (3l). Yield 60%; mp 215–216 1C; IR
(cm1, KBr): 3613, 3358 (N-H), 3031 (C-H), 1635 (C¼O), 1585
(C¼N); 1H NMR (DMSO-d6): δ 10.39 (s, 1H, CONH, D2O
exchangeable), 7.36–7.91 (m, 17H, Ar-H), 7.05 (s, 1H, pyrazole-
H-4), 6.12 (s, 2H, NH2, D2O exchangeable), 5.22 (s, 2H, OCH2),
2.12 (s, 3H, CH3);
13C NMR (DMSO-d6): δ 171.49 (C¼O),
160.55 (pyrazole C3), 159.66 (pyrazole C5), 151.08, 143.02,
138.54, 135.39, 135.17, 135.06, 130.52, 129.34, 128.72, 128.65,
128.43, 128.31, 125.08, 123.81, 121.31, 120.07, 117.32, 113.35,
105.04 (pyrazole C4), 71.97 (OCH2), 17.66 (CH3); ESI-MS (m/z):
490 [MþH]þ; Anal. Calcd. for C30H26N4O2: C, 75.93; H, 5.52; N,
11.81; Found: C, 75.97; H, 5.48; N, 11.83.
4.1.3.13. 1-[4-[5-(4-(Benzyloxy)phenyl)-1-(2,6-dimethylphenyl)-
1H-pyrazol-3-yl]phenyl]urea (3m). Yield 68%; mp 213–214 1C;
IR (cm1, KBr): 3628, 3349 (N-H), 3037 (C-H), 1635 (C¼O),esis, characterization and pharmacological evaluation of pyrazolyl urea
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exchangeable), 7.42–7.80 (m, 16H, Ar-H), 7.05 (s, 1H, pyrazole-
H-4), 6.18 (s, 2H, NH2, D2O exchangeable), 5.12 (s, 2H, OCH2),
2.11 (s, 6H, CH3);
13C NMR (DMSO-d6): δ 171.96 (C¼O),
160.91 (pyrazole C3), 159.27 (pyrazole C5), 152.56, 143.95,
137.53, 135.91, 135.08, 134.73, 129.31, 129.06, 128.56, 128.52,
128.37, 128.08, 125.37, 123.49, 122.06, 120.95, 118.78, 113.47,
105.25 (pyrazole C4), 71.82 (OCH2), 17.53 (2 CH3); ESI-MS
(m/z): 489 [MþH]þ; Anal. Calcd. for C31H28N4O2: C, 76.21; H,
5.78; N, 11.47; Found: C, 76.18; H, 5.71; N, 11.42.
4.1.3.14. 1-[4-[5-(4-(Benzyloxy)phenyl)-1-(2-methoxyphenyl)-
1H-pyrazol-3-yl]phenyl]urea (3n). Yield 55%; mp 240–241 1C;
IR (cm1, KBr): 3633, 3353 (N-H), 3029 (C-H), 1621 (C¼O),
1595 (C¼N); 1H NMR (DMSO-d6): δ 10.23 (s, 1H, CONH, D2O
exchangeable), 7.42–7.86 (m, 17H, Ar-H), 7.05 (s, 1H, pyrazole-
H-4), 6.23 (s, 2H, NH2, D2O exchangeable), 5.18 (s, 2HH, OCH2),
3.72 (s, 3H, OCH3);
13C NMR (DMSO-d6): δ 170.27 (C¼O),
159.76 (pyrazole C3), 151.32 (pyrazole C5), 143.01, 137.08,
134.96, 134.01, 133.12, 133.01, 130.63, 129.27, 128.87, 128.75,
128.69, 128.57, 125.36, 123.16, 122.53, 121.28, 118.03, 113.26,
105.68 (pyrazole C4), 70.65 (OCH2), 56.81 (OCH3); ESI-MS
(m/z): 491 [MþH]þ; Anal. Calcd. for C30H26N4O3: C, 73.45; H,
5.34; N, 11.42; Found: C, 73.41; H, 5.28; N, 11.47.
4.1.3.15. 1-[4-[5-(4-(Benzyloxy)phenyl)-1-(4-methoxyphenyl)-
1H-pyrazol-3-yl]phenyl]urea (3o). Yield 61%; mp 243–244 1C;
IR (cm1, KBr): 3345 (N-H), 3032 (C-H), 1673 (CONH), 1590
(C¼N); 1H NMR (DMSO-d6): δ 10.55(s, 1H, CONH, D2O
exchangeable), 7.42–7.91 (m, 17H, Ar-H), 7.05 (s, 1H, pyrazole-
H-4), 6.21 (s, 2H, NH2, D2O exchangeable), 5.21 (s, 2H, OCH2),
3.74 (s, 3H, OCH3);
13C NMR (DMSO-d6): δ 170.68 (C¼O),
159.63 (pyrazole C3), 152.61 (pyrazole C5), 143.68, 138.82,
134.62, 134.13, 134.06, 133.65, 130.54, 129.09, 128.75, 128.63,
128.51, 127.28, 124.19, 123.47, 122.01, 121.79, 119.12, 113.54,
103.21 (pyrazole C4), 72.05 (OCH2), 56.39 (OCH3); ESI-MS
(m/z): 491 [MþH]þ; Anal. Calcd. for C30H26N4O3: C, 73.45; H,
5.34; N, 11.42; Found: C, 74.38; H, 5.37; N, 11.46.
4.2. Pharmacology
p38α MAPK assay was performed using the CycLex p38 Kinase
assay kit (Cat CY-1177) procured from MBL, USA. CycLex p38α
positive control (Cat CY-E1177) was also purchased from MBL,
USA. The commercially available ELISA kit (Cat KB2052,
Krishgen Biosystems, Mumbai, India) was used for TNF-α
estimation in the mice plasma samples. LPS from Escherichia
coli 0111:B4 (Cat 9028) was obtained from Chondrex, USA. All
the pharmacological experiments were conducted in compliance
with ethical principles after Institutional Animal Ethics Committee
(IAEC, No. 173/CPCSEA, 2000) approval. Animals were obtained
from central animal house facility, Hamdard University, New
Delhi. The experiments were performed in albino rats of Wistar
strain of either sex, weighing 180–200 g. The animals were
maintained at 25 7 2 1C, 50 7 5% relative humidity and 12 h
light/dark cycle. Food and water were freely available up to the
time of experiments.
4.2.1. p38α MAPK assay
Inhibition of p38α MAPK activity was determined according to
the method of Forrer et al.25. All the samples were diluted with a
kinase buffer as needed. In the test sample wells kinase reactionPlease cite this article as: Somakala Kanagasabai, Amir Mohammad. Synth
derivatives as potential anti-inﬂammatory agents. Acta Pharmaceutica Sinicbuffer (80 mL) and 10 inhibitor compounds or standard
(SB 203580) (10 mL) were added. In the solvent control experi-
ment, 80 mL of kinase reaction buffer and 10 mL of solvent for
inhibitor were added. In the inhibition control wells, 80 mL of
kinase reaction buffer and 10 mL of 10 SB 203580 (20 mmol/L)
were added. The reaction in all wells was initiated by adding
10 mL of p38α positive control to each well and mixing thoroughly
at room temperature. The plate was covered and incubated at
30 1C for 30 min. The wells were washed ﬁve times with a wash
buffer. 100 mL of anti-phospho-ATF-2 Thr71 polyclonal antibody
PPT-09 was pipetted into each well, covered and incubated at
room temperature for 30 min. The wells were washed ﬁve times
with a wash buffer. HRP-conjugated anti-rabbit IgG (100 mL) was
pipetted into each well, covered and incubated at room tempera-
ture for 30 min. The wells were washed ﬁve times with a wash
buffer. 100 mL of substrate reagent (tetramethylbenzidine, TMB)
was added to each well and incubated at room temperature for 5–
15 min. Finally 100 mL of a stop solution (1 mol/L H2SO4) was
added to each well and absorbance was measured in each well
using a spectrophotometric plate reader at a wavelength of 450 nm.
IC50 values were calculated. All samples were assayed in
triplicates.
4.2.2. Antioxidant assay
All the compounds (3a–o) were evaluated for their in vitro free
radical scavenging activity by the 2,20-diphenyl-1-picrylhydrazyl
(DPPH) radical scavenging method described by Blois et al.26.
4.2.3. Anti-inﬂammatory activity
Compounds 3a–e, 3g and 3h were evaluated for their anti-
inﬂammatory activity by the carrageenan-induced rat paw edema
method of Winter et al.27 using Digital Plethysmometer-PLM-01
Plus (Orchid Scientiﬁcs and Innovatives India Pvt., Ltd., Mumbai,
India).
4.2.4. Ulcerogenic test and lipid peroxidation
The most active compound of the series 3a–e, 3g and 3h were
evaluated for their ulcerogenic potential in rats by already reported
procedure28,29. Lipid peroxidation in the gastric mucosa was
determined according to the already reported method of Ohkawa
et al.30.
4.2.5. TNF-α production inhibition evaluation
TNF-α production inhibition in mice (BALB/c) weighing 20–30 g
was carried out using the already reported procedure31,32.
4.2.6. Molecular docking study
To analyze the biological activity on the basis of structure,
molecular docking studies of the compounds were carried out by
taking X-ray crystal structure data to establish the interactions of
the compounds with the p38α MAPK (PDB code: 3D83 having
resolution of 1.90Âe). The molecular docking study was used to
understand the possible best binding pose of compounds (3a–o) by
which it could be sorted out for identifying promising p38α
MAPK inhibitor using Glide extra precision (XP) Maestro 10.1
Schrodinger, (2015-Release-4) running on the Linux 64 operating
system33. Molecular docking studies mainly involve selection and
preparation of appropriate protein, grid generation, ligand prepara-
tion followed by docking and analysis. The ligands and the
receptors were prepared using the LigPrep and Protein preparationesis, characterization and pharmacological evaluation of pyrazolyl urea
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and unwanted water molecules were also removed.
4.3. Statistical analysis
Results are expressed as the mean 7 SEM (standard error of the
mean) of six animals per group. The data obtained from
pharmacological experiments were analyzed using the Student's
t- test. A P value of less than 0.05 was considered statistically
signiﬁcant.
Acknowledgments
The authors are thankful to In-charge Animal House for providing
animals and In-charge, Central Instrumentation Facility (CIF) for
spectral analysis of compounds. The authors also thank Dr. Ozair
Alam, Assistant Professor in the Department of Pharmaceutical
Chemistry, Hamdard University, for carrying out docking studies.
One of the authors (Kanagasabai Somakala) is grateful to Depart-
ment of Science and Technology, Women Scientists Scheme-A
(File No. SR/WOS-A/CS-84/2013), New Delhi, for providing
ﬁnancial assistance.Appendix A. Supporting information
Supplementary data associated with this article can be found in the
online version at http://dx.doi.org/10.1016/j.apsb.2016.08.006.References
1. R. Medzhitov, Inﬂammation: new adventures of an old ﬂame, Cell
140, 2010, 771-776.
2. Bacchi S, Palumbo P, Sponta A, Coppolino MF. Clinical pharmacol-
ogy of non-steroidal anti-inﬂammatory drugs: a review. Antiinﬂamm
Antiallergy Agents Med Chem 2012;11:52–64.
3. Rubio-Perez JM, Morillas-Ruiz JM. A review: inﬂammatory process in
Alzheimer's disease, role of cytokines. Sci World J 2012;2012:756357.
4. Vane JR, Botting RM. Anti-inﬂammatory drugs and their mechanism
of action. Inﬂamm Res 1998;47:78–87.
5. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL.
Expression of a mitogen-responsive gene encoding prostaglandin
synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA
1991;88:2692–6.
6. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR.
TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss
3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase
homologue. J Biol Chem 1991;266:12866–72.
7. Dannhardt G, Kiefer W. Cyclooxygenase inhibitors-current status and
future prospects. Eur J Med Chem 2001;36:109–26.
8. Stillman MJ, Stillman MT. Choosing nonselective NSAIDs and
selective COX-2 inhibitors in the elderly. A clinical use pathway.
Geriatrics 2007;62:26–34.
9. Chakravarty S, Dugar S. Inc. Chapter 18. Inhibitors of p38α MAP
kinase. Annu Rep Med Chem 2002;37:177–86.
10. Amir M, Somakala K, Ali S. p38 MAP kinase inhibitors as anti
inﬂammatory agents. Min Rev Med Chem 2013;13:2082–96.
11. Chen Z, Gibson TB, Robinson F, Silvestro L, Pearson G, Xu B, et al.
MAP kinases. Chem Rev 2001;101:2449–76.
12. Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE.
Pharmacological proﬁle of SB 203580, a selective inhibitor of cytokine
suppressive binding protein/p38 kinase, in animal models of arthritis,Please cite this article as: Somakala Kanagasabai, Amir Mohammad. Synth
derivatives as potential anti-inﬂammatory agents. Acta Pharmaceutica Sinicbone resorption, endotoxin shock and immune function. J Pharmacol
Exp Ther 1996;279:1453–61.
13. Smith RJ. Therapies for rheumatoid arthritis: hope springs eternal.
Drug Discov Today 2005;10:1598–606.
14. Sticherling M. Mechanisms of psoriasis. Drug Discov Today: Dis
Mech 2005;2:275–81.
15. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor
superfamilies: integrating mammalian biology. Cell 2001;104:487–
501.
16. Xanthoulea S, Pasparakis M, Kousteni S, Brakebusch C, Wallach D,
Bauer J, et al. Tumor necrosis factor (TNF) receptor shedding controls
thresholds of innate immune activation that balance opposing TNF
functions in infectious and inﬂammatory diseases. J Exp Med
2004;200:367–76.
17. Zhou Y, Liu J, Zheng MY, Zheng SL, Jiang CY, Zhou XM, et al.
Structural optimization and biological evaluation of 1, 5-disubstituted
pyrazole-3-carboxamines as potent inhibitors of human 5-
lipoxygenase. Acta Pharm Sin B 2016;6:32–45.
18. Keche AP, Hatnapure GD, Tale RH, Rodge AH, Kamble VM.
Synthesis, anti-inﬂammatory and antimicrobial evaluation of novel
1-acetyl-3, 5-diaryl-4, 5-dihydro (1H) pyrazole derivatives bearing
urea, thiourea and sulfonamide moieties. Bioorg Med Chem Lett
2012;22:6611–5.
19. Moss N, Breitfelder S, Betageri R, Cirillo PF, Fadra T, Hickey ER,
et al. New modiﬁcations to the area of pyrazole-naphthyl urea based
p38 MAP kinase inhibitors that bind to the adenine/ATP site. Bioorg
Med Chem Lett 2007;17:4242–7.
20. Regan J, Capolino A, Cirillo PF, Gilmore T, Graham AG, Hickey E, et al.
Structure-activity relationships of the p38α MAP kinase inhibitor 1-(5-tert-
butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph-tha-
len-1-yl]urea (BIRB 796). J Med Chem 2003;46:4676–86.
21. Amir M, Kumar H, Javed SA. Condensed bridgehead nitrogen
heterocyclic system: synthesis and pharmacological activities of 1, 2,
4-triazolo-[3, 4-b]-1, 3, 4-thiadiazole derivatives of ibuprofen and
biphenyl-4-yloxy acetic acid. Eur J Med Chem 2008;43:2056–66.
22. Amir M, Saifullah K, Akhter W. Design, synthesis and pharmacolo-
gical evaluation of novel azole derivatives of aryl acetic acid as anti-
inﬂammatory and analgesic agents. J Enzym Inhib Med Chem
2011;26:141–8.
23. Amir M, Akhter MW, Alam O. Synthesis, characterization, and
biological evaluation of furoxan coupled ibuprofen derivatives as
anti-inﬂammatory agents. Monatsh Chem 2016;147:493–508.
24. Somakala K, Amir M, Sharma V, Wakode S. Synthesis and pharmacolo-
gical evaluation of pyrazole derivatives containing sulfonamide moiety.
Monatsh Chem 2016. Available from: http://dx.doi.org/10.1007/
s00706-016-1694-x.
25. Forrer P, Tamaskovic R, Jaussi R. Enzyme-linked immunosorbent
assay for measurement of JNK, ERK, and p38 kinase activities. Biol
Chem 1998;379:1101–11.
26. Blois MS. Antioxidant determination by the use of a stable free radical.
Nature 1958;181:1119–200.
27. Winter CA, Risely EA, Nuss GM. Carrageenin-induced edema in hind
paw of the rat as an assay for antiinﬂammatory drugs. Exp Biol Med
1962;111:544–7.
28. Bekhit AA, Fahmy HT, Rostom SA, Bekhit AE. Synthesis and
biological evaluation of some thiazolylpyrazole derivatives as dual
anti-inﬂammatory antimicrobial agents. Eur J Med Chem
2010;45:6027–38.
29. Cioli V, Putzolu S, Rossi V, Sorza Barcellona P, Corradino C. The role
of direct tissue contact in the production of gastrointestinal ulcers by
anti-inﬂammatory drugs in rats. Toxicol Appl Pharmacol
1979;50:283–9.
30. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal
tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351–8.
31. Griswold DE, Hilegass LM, O'Leary-Bartus L, Lee JC, Laydon JT,
Trophy TJ. Evaluation of human cytokine production and effects of
pharmacological agents in a heterologous system in vivo. J Immunol
Methods 1996;195:1–5.esis, characterization and pharmacological evaluation of pyrazolyl urea
a B (2016), http://dx.doi.org/10.1016/j.apsb.2016.08.006
Pyrazolyl urea derivatives as potential anti-inﬂammatory agents 1132. Nakao A, Ohkawa N, Nagasaki T, Kagari T, Doi H, Shimozato T,
et al. Tetrahydropyridine derivatives with inhibitory activity on the
production of proinﬂammatory cytokines: part 1. Bioorg Med Chem
Lett 2009;19:4607–10.Please cite this article as: Somakala Kanagasabai, Amir Mohammad. Synth
derivatives as potential anti-inﬂammatory agents. Acta Pharmaceutica Sinic33. Maestro V, Schrodinger LLC. Maestro, version 10.1. New York, NY:
Schrödinger LLC; 2015.esis, characterization and pharmacological evaluation of pyrazolyl urea
a B (2016), http://dx.doi.org/10.1016/j.apsb.2016.08.006
